|
|
Education
| 1986-1989 | School of Medicine University
of Colorado Denver, CO, Medical Degree |
| 1982-1986 | University of Colorado
Boulder Campus Boulder, CO, B.A. Biochemistry |
Post-Graduate Training:
| 1994-1996 | Fellowship in Infectious
Disease Section of Infectious Disease Department of Medicine University of Arizona Health Sciences Center Tucson, AZ |
| 1991-1993 | Residency in Internal Medicine,
Department of Internal Medicine Medical University of South Carolina Charleston, SC |
| 1990-1991 | Internship in Internal Medicine,
Department of Internal Medicine Medical University of South Carolina Charleston, SC |
Academic Appointments:
| 1996-2000 | Assistant Professor of Clinical
Medicine Section of Infectious Diseases Department of Internal Medicine University of Arizona Health Sciences Center Tucson, AZ |
| 1996-2000 | Director Special Immunology Program Section of Infectious Diseases Department of Internal Medicine University of Arizona Health Sciences Center Tucson, AZ |
HIV/AIDS Research:
1996 - Principal Investigator: HIV Proteinase Saquinovir
Protocol SV14604C. A randomized, multi-center, double-blind, Phase III, parallel
study of zidovudine (ZDV) alone, versus ZDV + zalcitabine (ddC), versus ZDV
+ ddC + Saquinovir in previously untreated or minimally pretreated HIV-infected
patients with CD4 counts from = 50 to = 350 cells/mm3.
1996- Principal Investigator: Protocol 807 Continuation Study of HIV-1 Immunogen
Studies. An open-labeled continuation study of the effect of HIV-1 Immunogen
in HIV-1 seropositive patients previously enrolled in IPL studies 103, 104,
201, 281 or IRC study 3G.
1997- Associate Investigator/Responsible Physician: Compassionate Use of Ambisome for the Treatment of Invasive Fungal Infections in Patients Intolerant to or with Disease Unresponsive to Standard Antifungal Therapy.
1998- Principal Investigator: Serostim Protocol 9037. A randomized, parallel group, double-blind, placebo-controlled, dose ranging, multi-center study of recombinant human growth hormone (Serostim) in the treatment of HIV-associated catabolism/wasting.
1998- Principal Investigator: Protocol NO. GS-97-423. A Randomized Expanded Access Program to Evaluate the Safety of Preveon (Adefovir Dipivoxil) at Two Dose Levels when used in Combination with other Antiretroviral Agents for the Treatment of Patients with HIV Infection who have Limited Treatment Options.
1998- Principal Investigator: 1592U89 Open Label Protocol for Adult Patients with HIV-1 Infection, Part B. An Open Label, Expanded Access Study Protocol to Document Adverse Medication Related Events.
